OUR LATEST NEWS
Get first-hand information about all the remarkable innovations by Tata MD and their coverage by the press here.
Tata MD & ADL partner to transform COVID testing
on 23/03/2021
Tata Medical and I Diagnostics (Tata MD) has collaborated with city-based Anderson Diagnostics and Labs to standardise the indigenously developed diagnostic kit Tata MD CHECK in a bid to slow down the rate of new COVID-19 infections. This is part of a wide ranging clinical collaboration between the two companies. The 'Made-in-India' Tata MD CHECK diagnostic kit can be scaled rapidly with Anderson Diagnostics Labs having already successfully conducted over 10,000 COVID-19 tests, using the DGCA approved Indian Council of Medical Research guidelines, novel diagnostic solution based on Feluda CRISPR Platform, a company statement said. "Tata's CRISPR-based platform is a rock-solid COVID test that can be programmed for early detection and treatment of a number of other diseases and conditions as well," Anderson Diagnostics and Labs Director Dr Srinivasaraman said.
Anderson Diagnostics launches Tata MD CHECK
on 23/03/2021
Tata Medical and Diagnostics (Tata MD), the new healthcare venture from the house of Tata, announced today that it has entered into a wide-ranging clinical collaboration with Chennai-based Anderson Diagnostics & Labs (ADL), to standardize the indigenously-developed Tata MD CHECK in a bid to slow down the rate of new infections. The collaboration with clinical experts of ADL has helped ensure that the "Made-in-India" Tata MD CHECK diagnostic kit can be scaled rapidly with ADL having already successfully conducted over 10,000 COVID tests using this new, DGCA approved ICMR guidelines, novel diagnostic solution based on Feluda CRISPR Platform. `Having tested and validated more than 10000 samples, we feel this technology is on par with the best in the world and futuristic as well. Moreover, Tata MD CHECK's ability to perform using inexpensive lab equipment like standard thermocyclers will be a boost for small labs in tier 11/111 towns and villages to start COVID testing locally" said Dr AnandKri shnamoorthy, Managing Director, Anderson Diagnostics. "Working with the exceptional team at Anderson Diagnostics has demonstrated the impact that a new technology-based product like Tata MD CHECK can have on strengthening our COVID testing capacity and access to testing in remote areas.Tata's clinical collaboration with Anderson Diagnostics will only drive advances in the diagnostic space of COVID-19 as the pandemic continues"said Girish Krishnainurthy, MD & CEO, Tata Medical and Diagnostics.
Tata Medical launches Feluda covid test kits under brand Check
on 09/11/2020
Tata Medical and Diagnostics Limited on Mon- 0. day launched its covid-I9 test under the brand Check. The paper-based test is powered by the Feluda technology it developed along with Council of Scientific and Industrial Research's constituent lab. Institute of Genomics and Integrative Biology (CSIR-IGIB).
Tata Group Rolls Out 'Faster COVID Tests'
on 09/11/2020
Tata Group launched a Covid test kit on Monday that it says will process results more easily and faster than the RT-PC12 method.
Tata Group Rolls Out 'Faster COVID Tests'
on 09/11/2020
Tata Group launched a Covid test kit on Monday that it says will process results more easily and faster than the RT-PC12 method.
Tata group launches `Feluda' test kits:
on 09/11/2020
Tate Medical and Diagnostics (Tata MD) announced the commercial launch of Tata MDCHECK. a diagnostic gene-based testing wit kit for Covid 19. It is powered by 'Feluda', a CRISPR Cas-9 technology developed by leading research institute. CSIR-IGIB. The company claims a quicker, simpler, and cheaper process as against the other technology. RT-PCR (Reverse transcription polymerase chain reaction) — considered the gold standard method for Covid 19 testing.
View More
Tata MD and Anderson Diagnostic Labs partner to transform COVID testing through Tata MD CHECK
on 21/03/2021
TataMD and Anderson Diagnostics and Labs establishes India’s first dedicated CRISPR-based COVID Testing Lab accredited by National Accreditation Board for Testing and Calibration Laboratories (NABL) at Hosur TataMD CHECK can be performed using conventional low cost lab equipment enabling COVID testing in small towns and villages CHENNAI, 22 March 2021: Tata Medical and Diagnostics (Tata MD), the new healthcare venture from the house of Tata, announced today that it has entered into a wide-ranging clinical collaboration with Chennai-based Anderson Diagnostics & Labs (ADL), to standardize the indigenously - developed TataMD CHECK in a bid to slow down the rate of new infections. The collaboration with clinical experts of ADL has helped ensure that the “Made-in-India” TataMD CHECK diagnostic kit can be scaled rapidly with ADL having already successfully conducted over 10,000 COVID tests using this new, DGCA approved ICMR guidelines, novel diagnostic solution based on Feluda CRISPR Platform. “Tata’s CRISPR-based platform is a rock-solid COVID test that can be programmed for early detection and treatment of a number of other diseases and conditions as well. The indigenously-developed Tata MD CHECK based on Feluda offers a clear, quicker and more accessible alternative to RT-PCR, the current mainstay of COVID-19 tests. Our clinical partnership with Tata MD will help support the transformation of COVID-19 testing to arrest the emergence of a second wave in India and around the world.” said Dr Srinivasaraman, Director, Anderson Diagnostics and Labs. “TataMD CHECK provides a high-quality testing experience with its simplicity, sensitivity, specificity and speed of results. We have performed COVID tests using TataMD CHECK and reported results well under three hours using, inexpensive lab equipment compared to current available molecular testing platforms. The application of CRISPR technology is a new era in molecular diagnostics.” said Dr Sachin Hongunitkar, Head of Anderson Clinical Genetics, Chennai. 'Having tested and validated more than 10000 samples, we feel this technology is on par with the best in the world and futuristic as well. Moreover, TataMD CHECK’s ability to perform using inexpensive lab equipment like standard thermocyclers will be a boost for small labs in tier II/III towns and villages to start COVID-19 testing locally” said Dr Anand Krishnamoorthy, Managing Director, Anderson Diagnostics. “Working with the exceptional team at Anderson Diagnostics has demonstrated the impact that a new technology-based product like Tata MD CHECK can have on strengthening our COVID-19 testing capacity and access to testing in remote areas. Tata’s clinical collaboration with Anderson Diagnostics will only drive advances in the diagnostic space of COVID-19 as the pandemic continues.” said Girish Krishnamurthy, MD & CEO, Tata Medical and Diagnostics. While RT-PCR tests have been a mainstay in testing for the global COVID-19, unfortunately, the sheer volume of tests demanded by the pandemic, coupled with the high expenses and skill sets required for setting up and operating RT PCR Labs has created a strong need for alternative testing methods. With its extensive experience in managing COVID for organizations and events, Tata MD also offers Tata MD SECURE, a holistic COVID management program designed for industries, corporate organizations, events (like sports, religious) and educational institutions. The entire program is intended for employee/ stakeholder wellbeing and event/business continuity. Tata MD SECURE is a proven working model for managing COVID-19 and the entire activity is supported by a robust digital platform, designed in consultation with eminent panel of scientists from India and other counties. ADL is a key diagnostic partner in helping several such corporates and industries foster safer workplaces as employees return to work. Girish Krishnamurthy, CEO & MD said, “The pandemic has affected not just the health of the people but also the economic health of the nation. It is essential that business and industry come back to a state of normal function to arrest the decline in the economy. However, the pandemic is still a matter of concern with the emergence of new strains and any return to normalcy needs to be undertaken with caution. The key, therefore, lies in significantly enhancing the testing capabilities with regular tests for employees, which would enable organisations to reduce exposure to sick employees and allay any fear of resuming work.” Against the backdrop of new COVID variants and the possible emergence of a second wave, about 70 districts of India have seen an increase of over 150% in the number of COVID cases in the past few weeks, and if the spike is not contained now, once again, we will experience a nationwide outbreak. Many of these towns are small towns/cities and villages including in Tamil Nadu, and need to be protected. The Honorable Prime Minister has asked the states to step up testing as one of the measures to contain COVID 19 second wave. Strong strategic partnerships allow each partner to bring in their strengths, creating a synergy that augments the efforts in the battle against COVID. The partnership between Tata MD and Anderson Diagnostics and Labs will act as an enabler to optimize delivery of the COVID tests, advance diagnosis for emerging pandemic and diseases, create more value for the people and allow easier access to the tests. Together with its partners, TataMD will drive change in healthcare through the latest technology and provide COVID-19 testing wherever and whenever needed. About Tata Medical and Diagnostics Ltd (Tata MD) Tata Medical and Diagnostics Ltd (Tata MD), the wholly-owned healthcare venture from the Tata Group, aims to provide leading-edge, patient-centric solutions to make healthcare access more reliable for consumers. Tata MD’s products and solutions will span different facets of a fast-evolving healthcare economy including the launch CRISPR-based innovative diagnostics, state-of-the-art medical devices as well as integrated ‘connected care’ solutions for rural and urban consumers. Launched during the 2020 pandemic, Tata MD has developed and launched Tata MD CHECK, the world’s first commercially available CRISPR Cas-9 based COVID-19 test, powered by FELUDA from CSIR-IGIB, a leading Indian biosciences research institute. About Tata MD CHECK Platform: Tata MD CHECK based on clustered regularly interspaced short palindromic repeats (CRISPR) technology — that tests for the novel coronavirus (SARS-CoV-2) in just about 75 minutes. Another key advantage of the TataMD CHECK test is that it can be performed in virtually any lab, using common lab equipment like thermo cyclers. This stands in stark contrast to qPCR-based tests, which require expensive, specialized equipment, limiting those tests to well-equipped diagnostic labs. Plus, the new TataMD CHECK test is easy to interpret: much like a store-bought pregnancy test, dark lines that appear on test strips indicate the presence of viral genes. TataMD CHECK provides high sensitivity and specificity and can also be performed using automated robots and in mobile laboratories. About Anderson Diagnostics & Labs Anderson Diagnostics & Labs is a doctor-driven diagnostic centre headquartered in Chennai since 2008. ADL focuses on providing high quality diagnostic services and preventive screening in oncology, Theranostics Clinical Genetics and Foetal medicine. ADL is also a renowned pathology centre for various laboratory studies and services. During the past 12 months, ADL has worked successfully conducted 200000+ COVID-19 tests for the Government as well as public.
Tata MD CHECK to make COVID-19 detection simpler, quicker and more accessible
on 08/11/2020
- Gene-based Technology: World’s first viral diagnostic based on FELUDA CRISPR Cas-9 platform - Quality Product: Tata MD CHECK testing – Simple, Reliable & Scalable - Integrated Solution: End-to-end, Traceable, Transparent and Trusted Mumbai, November 9, 2020… Tata Medical and Diagnostics Ltd. (Tata MD), the healthcare venture from Tata Group, has announced the commercial launch of Tata MD CHECK, a novel diagnostic testing for COVID-19. Tata MD CHECK is powered by FELUDA, a CRISPR Cas-9 technology that was developed in India by CSIR- IGIB for COVID testing. It is the world’s first CRISPR Cas-9 based diagnostic tool to be launched globally. Within a short span of 100 days from licensing the technology to its commercial launch, intense collaboration between the CSIR-IGIB team, other reputed scientific research bodies and the Tata MD R&D team helped develop, a compelling end-to-end diagnostic solution that will set the new standard in testing. It has been developed with secure supply-chains backed with a layer of digital services. Tata MD CHECK has been approved by Indian Council of Medical Research and Drug Controller General of India (DCGI) and will be available through diagnostic centres and hospitals across India shortly. Tata MD CHECK is a lab test and uses CRISPR-Cas9 Technology. The process of collecting patient samples, RNA extraction and amplification etc remain same but uses simple, less expensive equipment and produces quicker results due to a more agile process and AI-based automated result detection. The key advantages of TataMD Check testing are: Simplicity: It is a paper strip-based test with an image-based visual result read out. It requires standard laboratory equipment and small batches of tests can be conducted. Quick Results: Fast reaction time of 45-50 minutes in the laboratory and the total testing time from RNA-extracted sample in the lab to result is 75 minutes only. Scalability: Ability to provide high quality, quick results using standard equipment and minimally trained staff allows for rapid adoption and scale with potential to reach remote locations of the country. Digital backbone: Continuous quality control using sensors and AI-based result reporting tool will help patients and authorities with the evidence of test, traceability of the sample and results accessible anywhere on cloud storage. A New Paradigm for the Diagnostic Industry Tata MD CHECK offers laboratories, hospitals and other healthcare providers to fast-track COVID diagnosis services to more people. It allows diagnostic centres to offer Covid-19 testing solutions at more locations due to two reasons: Lower capital costs since the testing can be done on standard available equipment instead of expensive qPCR machines. Hence new testing centres that are closer to the consumers in Tier II & III cities as also semi-rural areas can be set up Technology-backed faster test process: Quicker Results and Higher Throughput of testing volumes gives greater agility for labs as there are no minimum batch sizes Commenting on the launch, Girish Krishnamurthy, CEO, Tata Medical and Diagnostics said, “Tata MD aims to be a trusted, long term partner and help shape the evolution of healthcare industry towards building a more inclusive and integrated patient-centric model. With TataMD CHECK, we are committed to significantly enhance the testing experience of the consumers as well as work with laboratories and hospitals to ensure wider availability and easier access to testing. The pandemic has encouraged us to reflect on the healthcare sector and our role in bridging the many gaps that exists. Our collaboration with R&D institutions will continue to be a critical part of our strategy to introduce new diagnostic technologies like CRISPR, and develop R&D-led healthcare solutions for consumers for COVID and other infectious diseases.” Tata MD Check test kits will be manufactured at a quality-controlled production facility near Chennai, Tamil Nadu. The production plant presently has a capacity of producing 1 million kits in a month. Tata MD is also typing up with leading diagnostic chains, hospitals, healthcare centres to enhance the adoption of these tests apart from partnering with Government agencies. About Tata Medical and Diagnostics Ltd (Tata MD) Tata Medical and Diagnostics Ltd (Tata MD), the wholly-owned healthcare venture from the Tata Group, aims to provide leading-edge, patient-centric solutions to make healthcare access more reliable for consumers. Tata MD’s products and solutions will span different facets of a fast-evolving healthcare economy including the launch CRISPR-based innovative diagnostics, state-of-the-art medical devices as well as integrated ‘connected care’ solutions for rural and urban consumers.Launched during the 2020 pandemic, Tata MD has developed and launched Tata MD CHECK, the world’s first commercially available CRISPR Cas-9 based COVID-19 test, powered by FELUDA from CSIR-IGIB, a leading Indian biosciences research institute.